MedTrace Logo

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) of JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.

Conditions

  • Colorectal Neoplasms
  • Gastrointestinal Neoplasms

Interventions

DRUG

JNJ-89402638

JNJ-89402638 will be administered.

DRUG

Bevacizumab

Bevacizumab or biosimilar will be administered.

DRUG

FOLFOX

Chemotherapy agent FOLFOX will be administered.

DRUG

FOLFIRI

Chemotherapy agent FOLFIRI will be administered.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2028-02-25
Completion
2028-07-19
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06663319 on ClinicalTrials.gov